Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Duality Licenses ADC Platform to Adcendo for Mesenchymal Cancer Program

publication date: Jan 6, 2023

Duality Biologics, a Princeton-Shanghai biotech, granted a license to Copenhagen’s Adcendo for its proprietary DITAC (Duality Immune Toxin Antibody Conjugates) platform. Adcendo will use the platform to generate ADCs for its lead uPARAP-ADC program in mesenchymal cancers. Duality says the platform generates candidates with superior safety, sustainable payload delivery in tumors and efficient bystander killing of antigen cells. Duality will receive an upfront payment, milestones and tiered royalties on sales, though no details were disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital